Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Probiotic formula settles well

This article was originally published in The Tan Sheet

Executive Summary

Results of Nestle-sponsored research show an experimental infant formula containing a probiotic was as "safe and well-tolerated" as the control formula provided for seven months to infants who were not breast fed after each was 14 days old. The 55 infants in the control group and the 42 in the experimental group showed equivalence in mean weight gain and no statistically significant differences in recumbent length, head circumference or incidence of adverse events, according to Giuseppe Puccio, M.D., of the University of Palermo's Neonatology Institute of Obstetrics, Italy, et al. Additionally, infants in the probiotic group had fewer constipation problems and "had stool characteristics that suggest that the experimental formula was tolerated well," the researchers say. The study was conducted to determine whether the establishment of an intestinal microbiota in the gastrointestinal tract can come from using formula with a probiotic similar to the bifidobacteria created by non-digestible oligosaccharides in human breast milk. The control formula was Nestle's Nan starter formula and the experimental formula was Nan plus units of BL999 probiotic and a mixture of 90% galacto- and 10% fructo-oligosaccharides, according to the study published in the January issue of Nutrition...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100169

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel